Paid Clinical Trials Boulder

Discover 1,548 paid clinical trials in Boulder, Colorado. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,548

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionA Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Recruiting

PHASE1

PHASE2

Sponsor:

Amgen

Location:

Aurora CO, Irving TX, Dallas TX, Tyler TXshow 9 more

Code:

NCT05325866

Conditions

Solid Tumors

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Bemarituzumab

A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

Recruiting

PHASE2

PHASE3

Sponsor:

Cytokinetics

Location:

Aurora CO, Omaha NE, Kansas City MO, Dallas TXshow 18 more

Code:

NCT06412666

Conditions

Pediatric

Symptomatic Obstructive Hypertrophic Cardiomyopathy

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Aficamten

Placebo

Tocilizumab in Children With ACPTocilizumab in Children With ACP

Recruiting

EARLY_PHASE1

Sponsor:

University of Colorado, Denver

Location:

Aurora CO

Code:

NCT03970226

Conditions

Adamantinomatous Craniopharyngioma

Eligibility Criteria

Sex: All

Age: 2 - 21

Healthy Volunteers: Not accepted

Interventions

Tocilizumab

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineA Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Aurora CO, Logan UT, Ammon ID, Wichita KSshow 41 more

Code:

NCT04616326

Conditions

Chronic Migraine

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Galcanezumab

Placebo

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

Recruiting

PHASE3

Sponsor:

VistaGen Therapeutics, Inc.

Location:

Denver CO, Albuquerque NM, Las Vegas NV, Dallas TXshow 12 more

Code:

NCT06615557

Conditions

Social Anxiety Disorder (SAD)

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Fasedienol Nasal Spray

Placebo Nasal Spray

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaStudy to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Recruiting

PHASE1

PHASE2

Sponsor:

C4 Therapeutics, Inc.

Location:

Denver CO, Phoenix AZ, Rochester MN, Saint Louis MOshow 7 more

Code:

NCT04756726

Conditions

Multiple Myeloma

Lymphoma, Non-Hodgkin's

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

cemsidomide

Dexamethasone Oral

Fibrostenotic Eosinophilic Esophagitis: Assessment ToolsFibrostenotic Eosinophilic Esophagitis: Assessment Tools

Recruiting

Sponsor:

University of Colorado, Denver

Location:

Aurora CO

Code:

NCT02453126

Conditions

Eosinophilic Esophagitis

Eligibility Criteria

Sex: All

Age: 5 - 18

Healthy Volunteers: Not accepted

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABGAnticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Recruiting

PHASE3

Sponsor:

Icahn School of Medicine at Mount Sinai

Location:

Aurora CO, Murray UT, Salt Lake City UT, Tulsa OKshow 45 more

Code:

NCT04045665

Conditions

Atrial Fibrillation

Stroke

Bleeding

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Antiplatelet-only strategy

Oral Anticoagulant plus background antiplatelet therapy

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Denver CO, Aurora CO, Basalt CO, Rapid City SDshow 172 more

Code:

NCT05026866

Conditions

Alzheimer Disease

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Not accepted

Interventions

Donanemab

Placebo

Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)

Recruiting

Sponsor:

North Texas Veterans Healthcare System

Location:

Denver CO, Lubbock TX, Omaha NE, Oklahoma City OKshow 7 more

Code:

NCT02660866

Conditions

Peripheral Arterial Disease

Eligibility Criteria

Sex: All

Age: 40 - 70+

Healthy Volunteers: Not accepted

Interventions

Placebo + background APT + SMT

Vorapaxar 2.08 mg/d + background APT + SMT.